A new study by Cutting Edge Information found that 20% of pharmaceutical companies and CROs report challenges with patient engagement, internal processes and timelines. And almost one third (28%) of surveyed companies reported limited resources being an issue for a patient-centric approach.
Aligning company culture with patient-centric ideals (16%), facing external regulations (12%) and developing proper strategy (12%) were among the key obstacles companies face when it comes to patient centricity.
"The definition of patient-centricity is changing to meet customer demands in the life science industry," said Adam Bianchi, senior director of research at Cutting Edge Information.
"This entails operational challenges and opportunities for improvement. However, companies need to find what patient-centric means in terms of their operations and be able to show the success of customer-focused initiatives."
More than ever, pharmaceutical research needs to focus on individual differences, stepping away from a one-size-fits-all approach that may leave patients feeling disregarded. Genuine patient-centricity revolves around understanding a patient’s first-hand experience of his or her condition, and applying it toward a positive healthcare outcome.
As part of our latest initiative, Patient Primary, we have been researching the key reasons patients drop out of clinical trials in order to provide a truly patient-centric service, built by a deeper understanding of the struggles faced during clinical trials.
Patient Primary is designed to help pharmaceutical companies and CROs provide a white-glove service to their patients, making their lives easier and increasing retention and boosting enrollment.
Services include specialist patient travel to and from the site, provision of home nursing globally, tailored reports, app technology and more.
To learn how we can help boost the success of your next clinical trial by truly putting your patients first, get in touch today.